Ironwood (IRWD) PFO Ronald Silver receives 25,000-share restricted stock grant

Rhea-AI Filing Summary

Silver Ronald reported acquisition or exercise transactions in this Form 4 filing.

IRONWOOD PHARMACEUTICALS INC executive Ronald Silver, who serves as PFO & PAO, received a grant of 25,000 shares of Common Stock in the form of restricted stock units. The award was granted at a price of $0.00 per share as equity compensation.

The restricted stock unit award vests in two equal installments, with 50% of the underlying Class A Common Stock vesting on each approximate anniversary of the grant date. After this award, Silver directly holds 441,570 shares of the company’s Common Stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Silver Ronald

Role PFO & PAO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,000	$0.00	--

Holdings After Transaction: Common Stock — 441,570 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 25,000 shares Grant price: $0.00 per share Post-transaction holdings: 441,570 shares +1 more

4 metrics

RSU grant size 25,000 shares Restricted stock unit award of Common Stock

Grant price $0.00 per share Equity compensation grant price

Post-transaction holdings 441,570 shares Total Common Stock directly held after grant

Vesting schedule 50% per anniversary Two equal installments on each approximate anniversary

Key Terms

restricted stock unit, Class A Common Stock, grant, award, or other acquisition, non-derivative

4 terms

restricted stock unit financial

"The restricted stock unit award vests as to 50% of the shares"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Class A Common Stock financial

"shares of Class A Common Stock on each approximate anniversary"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

non-derivative financial

""transaction_type": "non-derivative""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Silver Ronald

(Last) (First) (Middle)

C/O IRONWOOD PHARMACEUTICALS, INC.

100 SUMMER STREET, SUITE 2300

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IRONWOOD PHARMACEUTICALS INC [ IRWD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PFO & PAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		A(1)		25,000	A	$0	441,570	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock unit award vests as to 50% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.

Remarks:

Principal Financial Officer and Principal Accounting Officer

	/s/ Amir Vitale, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did IRWD executive Ronald Silver report on this Form 4?

Ronald Silver reported receiving a grant of 25,000 shares of IRWD Common Stock as a restricted stock unit award. The grant was recorded at $0.00 per share and is part of his equity-based compensation, rather than an open-market purchase or sale of shares.

How do Ronald Silver’s new IRWD restricted stock units vest?

The restricted stock unit award vests in two equal installments of Class A Common Stock. According to the disclosure, 50% of the granted shares vest on each approximate anniversary of the grant date, creating a two-year vesting schedule that encourages ongoing service with Ironwood Pharmaceuticals.

How many IRWD shares does Ronald Silver own after this reported grant?

Following the reported grant, Ronald Silver directly holds 441,570 shares of Ironwood Pharmaceuticals Common Stock. This total reflects his position after adding the 25,000-share restricted stock unit award, highlighting a substantial ongoing equity stake aligned with the company’s long-term performance.

Was the IRWD Form 4 transaction an open-market buy or sell of shares?

The transaction was not an open-market buy or sell; it was coded as a grant or award acquisition. The 25,000 shares of Common Stock were granted at $0.00 per share as restricted stock units, representing compensation rather than a discretionary market transaction by Ronald Silver.

Does this IRWD Form 4 show any derivative securities or option exercises?

This filing does not report any derivative security transactions or option exercises for Ronald Silver. The derivative section is empty, and the only activity disclosed is the non-derivative grant of 25,000 restricted stock units settling in shares of Ironwood Pharmaceuticals Common Stock.